BridgeBio Pharma, Inc. (BBIO)

Market Cap	14.89B +121.3%
Revenue (ttm)	353.78M +62.5%
Net Income	-797.12M
EPS	-4.18
Shares Out	192.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,344,493
Open	78.85
Previous Close	79.10
Day's Range	76.74 - 80.00
52-Week Range	28.33 - 81.33
Beta	1.17
Analysts	Strong Buy
Price Target	78.81 (+1.98%)
Earnings Date	Feb 19, 2026

About BBIO

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 730
• Stock Exchange: NASDAQ
• Ticker Symbol: BBIO
• Website: https://bridgebio.com

Financial Performance

In 2024, BridgeBio Pharma's revenue was $221.90 million, an increase of 2285.27% compared to the previous year's $9.30 million. Losses were -$535.76 million, -16.70% less than in 2023.

Analyst Summary

According to 21 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price target is $78.81, which is an increase of 1.98% from the latest price.

Price Target

$78.81

(1.98% upside)

Analyst Consensus: Strong Buy